Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔ [CYP3A4 inhibitor] The effect of voriconazole on either erythromycin or azithromycin is unknown. Rifabutin Concomitant use of voriconazole [potent CYP450 inducer] and rifabutin should be avoided Voriconazole Cmax  69% unless the benefit outweighs the 300 mg QD Voriconazole AUC  78% risk. The maintenance dose of Compared to voriconazole 200 mg voriconazole may be increased to 300 mg QD (coadministered BID, 5 mg/kg intravenously BID or with voriconazole 350 mg Voriconazole Cmax  4% from 200 mg to 350 mg orally BID)* Voriconazole AUC  32% BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood Rifabutin Cmax  195% counts and adverse reactions to 300 mg QD (coadministered Rifabutin AUC  331% rifabutin (e.g., uveitis) is with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is BID)* BID, coadministered with voriconazole. Voriconazole Cmax  104% Voriconazole AUC  87% Rifampicin (600 mg QD) Voriconazole Cmax  93% Contraindicated (see section [potent CYP450 inducer] Voriconazole AUC  96% 4.3) Anti-cancer agents Glasdegib Although not studied, voriconazole If concomitant use cannot be [CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG concentrations of glasdegib and monitoring is recommended (see increase risk of QTc prolongation. section 4.4). Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is [CYP3A4 substrate] may increase tretinoin recommended during treatment concentrations and increase risk of with voriconazole and after its adverse reactions (pseudotumor discontinuation. cerebri, hypercalcaemia). 11 Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity. Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 43–44

HOS-109538 · Präparat HOS-093201

43 Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenprocoumon (HOS-091031) prothrombin (HOS-085093) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) mephobarbital (HOS-109457)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5ae9bbe0daf742daaf2a160c7d91f0c8d54a2ad8a7e98684c6f63198d04c2a65 · Zeichen 10221–11996 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75–76

HOS-109603 · Präparat HOS-093201

75 Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity. Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) vinblastine (HOS-086220) vincristine (HOS-086219) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6b81055f3c718e14857cfd38d70a912e61bf8acd5f789552e442ecbfbe65b67 · Zeichen 7792–11614 im Abschnitt

Wechselwirkungen · Emend

EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6

HOS-112526 · Präparat HOS-093697

Induction As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation and treatment. This effect may become apparent only after the end of a 3-day treatment with EMEND. For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment. The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of EMEND treatment. Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 06b9369c697bb573f6c8dcd6de97a932ec90843bd807852c1a1204fb206868b6 · Zeichen 6274–7181 im Abschnitt

Wechselwirkungen · Emend

EMEND 125 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 23

HOS-112584 · Präparat HOS-093697

Induction As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation and treatment. This effect may become apparent only after the end of a 3-day treatment with EMEND. For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment. The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of EMEND treatment. Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 06b9369c697bb573f6c8dcd6de97a932ec90843bd807852c1a1204fb206868b6 · Zeichen 6219–7126 im Abschnitt

Wechselwirkungen · Revatio

Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-114948 · Präparat HOS-094193

No interactions were observed between sildenafil (100 mg single dose) and acenocoumarol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage e9383153a10956ee47912d1d8d504d2ac5ed521b9fdf36bb16a362d89a9e122b · Zeichen 7096–7184 im Abschnitt

Wechselwirkungen · Revatio

Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 28

HOS-115011 · Präparat HOS-094193

No interactions were observed between sildenafil (100 mg single oral dose) and acenocoumarol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 9821fc493d35fb73042d5d0ec8ae759c1daffe0fc5b441bc42d2f81afd7bfa1e · Zeichen 7959–8052 im Abschnitt

Wechselwirkungen · Revatio

Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 46

HOS-115069 · Präparat HOS-094193

No interactions were observed between sildenafil (100 mg single dose) and acenocoumarol.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage e9383153a10956ee47912d1d8d504d2ac5ed521b9fdf36bb16a362d89a9e122b · Zeichen 7154–7242 im Abschnitt

Wechselwirkungen · Ivemend

IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 8

HOS-117446 · Präparat HOS-094609

Induction The fosaprepitant 150 mg single dose did not induce CYP3A4 on Days 1 and 4 in the midazolam interaction study. It is anticipated that IVEMEND would cause less or no greater induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6-8 days after first aprepitant dose has been observed. The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with IVEMEND.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aprepitant (HOS-112506) ethinyl estradiol (HOS-088135) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage a6ffd4af5692deeac0552c1100f062fec5a08edfc14f93a5d49caeba766074f3 · Zeichen 5437–6259 im Abschnitt

Wechselwirkungen · Rasilez

Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-208758 · Präparat HOS-154177

Pharmacokinetic interaction with other medicinal products Compounds that have been investigated in clinical pharmacokinetic studies include acenocoumarol, atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate and hydrochlorothiazide. No interactions have been identified.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) celecoxib (HOS-113199) allopurinol (HOS-089178) hydrochlorothiazide (HOS-086937) pioglitazone (HOS-089663) acenocoumarol (HOS-109456)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-02T02:00:00Z · SHA-256 4518ee1f6936dd9da7c06dbb3fa8bed38b206400f5cb767391af486f27614e43 · Passage c90c1997b523b2478493deffe990dfc7c057d04326fce2aaa50862a189db9dc6 · Zeichen 7431–7721 im Abschnitt

Wechselwirkungen · Efavirenz Teva

Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15

HOS-215298 · Präparat HOS-155418

Famotidine/efavirenz (40 mg single dose/400 mg single dose) ANTIANXIETY AGENTS Lorazepam/efavirenz Lorazepam: No dose adjustment is necessary (2 mg single dose/600 mg once AUC: ↑ 7% (↑ 1 to ↑ 14) for either medicinal product. daily) Cmax: ↑ 16% (↑ 2 to ↑ 32) These changes are not considered clinically significant. ANTICOAGULANTS Warfarin/efavirenz Interaction not studied. Plasma Dose adjustment of warfarin or Acenocoumarol/efavirenz concentrations and effects of warfarin acenocoumarol may be required. or acenocoumarol are potentially increased or decreased by efavirenz. ANTICONVULSANTS Carbamazepine/efavirenz Carbamazepine: No dose recommendation can be (400 mg once daily/600 mg once AUC: ↓ 27% (↓ 20 to ↓ 33) made. An alternative daily) Cmax: ↓ 20% (↓ 15 to ↓ 24) anticonvulsant should be Cmin: ↓ 35% (↓ 24 to ↓ 44) considered. Carbamazepine plasma levels should be Efavirenz: monitored periodically. AUC: ↓ 36% (↓ 32 to ↓ 40) Cmax: ↓ 21% (↓ 15 to ↓ 26) Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) lorazepam (HOS-085981) famotidine (HOS-112087) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage b7046270208170b0385a17c0e918d1ad0c21240b03d2ae096d59ee7e5908a72d · Zeichen 39935–41859 im Abschnitt

Wechselwirkungen · Xtandi

Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 6

HOS-127857 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3973–4850 im Abschnitt

Wechselwirkungen · Xtandi

Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36

HOS-127925 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3974–4851 im Abschnitt

Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)

Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 12–13

HOS-130945 · Präparat HOS-096981

12 Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax ↓ 49% phenytoin plasma levels is Voriconazole AUCτ ↓ 69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenprocoumon (HOS-091031) prothrombin (HOS-085093) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) mephobarbital (HOS-109457)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage 3007c8cb9219618b891e4357c16bc6e7421cdecc5c849ed6015399282b398983 · Zeichen 10139–11899 im Abschnitt

Wechselwirkungen · Ozempic

Ozempic 0.25 mg solution for injection in pre-filled pen Ozempic 0.5 mg solution for injection in pre-filled pen Ozempic 1 mg solution for injection in pre-filled pen Ozempic 2 mg solution for injection in pre-filled pen Ozempic 0.25 mg solution for injection in pre-filled syringe Ozempic 0.5 mg solution for injection in pre-filled syringe Ozempic 1 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 7

HOS-135971 · Präparat HOS-097800

Semaglutide did not change the overall exposure or Cmax of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-08-25T12:02:00Z · SHA-256 57219aa6be0c50a4f2cc98001152ec6dcce36b4e4c6ae43650c37f58899b3d2c · Passage 9881cb2ab5bee6613ce050387ae9c3c200ab0f2bd2c38bc40a12a94488ad8017 · Zeichen 1998–2517 im Abschnitt

Wechselwirkungen · Rybelsus

Rybelsus 1.5 mg tablets Rybelsus 4 mg tablets Rybelsus 9 mg tablets Rybelsus 25 mg tablets Rybelsus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-143115 · Präparat HOS-098932

Warfarin and other coumarin derivatives Semaglutide did not change the AUC or Cmax of R- and S-warfarin following a single dose of warfarin, and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-22T10:41:00Z · SHA-256 92f8cd4bbfc5e1b56bb6383ebaaeb7f5b41beee2ff07448d020f2af2ee2b7172 · Passage c37a1a83754f73ab29ef0dbbb8cb888e6b1884e285c79930711b980a6ba78f56 · Zeichen 508–1046 im Abschnitt

Wechselwirkungen · Rybelsus

Rybelsus 3 mg tablets Rybelsus 7 mg tablets Rybelsus 14 mg tablets Rybelsus 25 mg tablets Rybelsus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 30

HOS-143154 · Präparat HOS-098932

Warfarin and other coumarin derivatives Semaglutide did not change the AUC or Cmax of R- and S-warfarin following a single dose of warfarin, and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-22T10:41:00Z · SHA-256 92f8cd4bbfc5e1b56bb6383ebaaeb7f5b41beee2ff07448d020f2af2ee2b7172 · Passage c37a1a83754f73ab29ef0dbbb8cb888e6b1884e285c79930711b980a6ba78f56 · Zeichen 508–1046 im Abschnitt

Wechselwirkungen · Wegovy

Wegovy 0.25 mg solution for injection in pre-filled pen Wegovy 0.5 mg solution for injection in pre-filled pen Wegovy 1 mg solution for injection in pre-filled pen Wegovy 1.7 mg solution for injection in pre-filled pen Wegovy 2.4 mg solution for injection in pre-filled pen Wegovy 7.2 mg solution for injection in pre-filled pen Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen Wegovy 1 mg FlexTouch solution for injection in pre-filled pen Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen Wegovy 0.25 mg solution for injection in pre-filled syringe Wegovy 0.5 mg solution for injection in pre-filled syringe Wegovy 1 mg solution for injection in pre-filled syringe Wegovy 1.7 mg solution for injection in pre-filled syringe Wegovy 2.4 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 9

HOS-147301 · Präparat HOS-099634

Semaglutide did not change overall exposure or Cmax of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 6ac51a3252fb438154834f042c1c33ae98244447c61078fbb44f0c986154c160 · Zeichen 2105–2620 im Abschnitt

Wechselwirkungen · Wegovy

Wegovy 1.5 mg tablets Wegovy 4 mg tablets Wegovy 9 mg tablets Wegovy 25 mg tablets · Abschnitt 4.5 · PDF-Seite 44

HOS-147342 · Präparat HOS-099634

Warfarin and other coumarin derivatives Semaglutide did not change the AUC or Cmax of R- and S-warfarin following a single dose of warfarin, and the pharmacodynamic effects of warfarin as measured by the international normalised ratio (INR) were not affected in a clinically relevant manner. However, cases of decreased INR have been reported during concomitant use of acenocoumarol and semaglutide. Upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of INR is recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) acenocoumarol (HOS-109456) warfarin (HOS-085950)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage c37a1a83754f73ab29ef0dbbb8cb888e6b1884e285c79930711b980a6ba78f56 · Zeichen 508–1046 im Abschnitt

Wechselwirkungen · Enzalutamide Viatris

Enzalutamide Viatris 40 mg film-coated tablets Enzalutamide Viatris 80 mg film-coated tablets Enzalutamide Viatris 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-152525 · Präparat HOS-100781

Groups of medicinal products that can be affected include, but are not limited to: • Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-23T15:00:00Z · SHA-256 9ec2075aeb7a3bf9d945f1434168aa948ef3cdae81a1cefa92c76a3324997d49 · Passage bfc103097c88d7d8aeea8e7e62639ae12301bc9736ef551eb28e5ea67198b6ec · Zeichen 3904–4850 im Abschnitt

Quellenpassagen (20)

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Emend

Wechselwirkungen · Emend

Wechselwirkungen · Revatio

Wechselwirkungen · Revatio

Wechselwirkungen · Revatio

Wechselwirkungen · Ivemend

Wechselwirkungen · Rasilez

Wechselwirkungen · Efavirenz Teva

Wechselwirkungen · Xtandi

Wechselwirkungen · Xtandi

Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)

Wechselwirkungen · Ozempic

Wechselwirkungen · Rybelsus

Wechselwirkungen · Rybelsus

Wechselwirkungen · Wegovy

Wechselwirkungen · Wegovy

Wechselwirkungen · Enzalutamide Viatris